Before we begin, I would like to inform you ... can lead to 19% total body weight loss at eight months or four months after the Allurion Balloon passes. A double line, randomized controlled ...

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first ... the first month and 58% discontinue before reaching a clinically meaningful ...

2024 when Chardan Capital changed their price target from N/A to N/A for Allurion Technologies Inc. Analysts arrive at stock ratings after doing extensive research, which includes going through ...

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1 ...

Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...

ALLURION TECHNOLOGIES ($ALUR) posted quarterly earnings results on Wednesday, March 26th. The company reported earnings of -$7.00 per share, missing estimates of -$5. ...

Before we begin, I would like to inform you ... lead to 19% total body weight loss at eight months or four months after the Allurion Balloon passes. A double line randomized controlled study ...

Allurion Technologies Inc (NYSE:ALUR) resumed sales in France after regulatory clearance, which is expected to contribute to future revenue growth. The company raised additional capital, providing a ...

Hello, everyone, and welcome to Allurion fourth quarter earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session.